Glioblastoma Cells Do Not Affect Axitinib-Dependent Senescence of HUVECs in a Transwell Coculture Model

Axitinib is an orally available inhibitor of tyrosine kinases, with high specificity for vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3. It is approved for the treatment of advanced renal cell carcinoma and is in phase II clinical trials for recurrent glioblastoma (GBM). GBM is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Merolle, Matilde, Mongiardi, Maria Patrizia, Piras, Maurizia, Levi, Andrea, Falchetti, Maria Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073100/
https://www.ncbi.nlm.nih.gov/pubmed/32098270
http://dx.doi.org/10.3390/ijms21041490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073100/
https://www.ncbi.nlm.nih.gov/pubmed/32098270
http://dx.doi.org/10.3390/ijms21041490

Ejemplares similares